

## **CONCLUSION**

- 1- Diuretic-intractable ascites is more common than diuretic-resistant ascites as a type of refractory ascites.
- 2- Hypotension, hepatic encephalopathy, and renal impairment are the major causes of inability to increase the dose of diuretics in diuretic-intractable ascites.
- 3- Suggested precipitating factors responsible for refractory ascites include liver failure or advancement of liver cirrhosis; infection; electrolyte imbalance such as hyponatremia and hyperkalemia; renal impairment; and superadded complications of cirrhosis such as portal vein thrombosis and hepatocellular carcinoma.

## **RECOMMENDATIONS**

- 1- Wide scale multicenter studies are needed to evaluate the precipitating factors responsible for refractory ascites in cirrhotic patients.
- 2- Before the precise diagnosis of refractory ascites we should investigate for a superadded complication of cirrhosis such as portal vein thrombosis and hepatocellular carcinoma which may cause rapid accumulation of ascites.

---

## REFERENCES

1. Anthony PP, Ishak KG, Nayak NC, et al. The morphology of cirrhosis: recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. *J Clin Pathol* 1978; 31:395–414.
2. Marmur J, Bergquist A, Stal P. Liver transplantation of patients with cryptogenic cirrhosis: clinical characteristics and outcome. *Scand J Gastroenterol* 2010; 45:60–69.
3. Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. *Hepatology* 1987; 7:122–128.
4. Albers I, Hartman H, Bircher J, Creutzfeldt. Superiority of the Child–Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. *Scand J Gastroenterol* 1989; 24:269–276.
5. D’Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. *Hepatology* 1995; 22:332–351.
6. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. *Hepatology* 2001; 33:464–470.
7. Runyon, BA. Management of adult patients with ascites due to cirrhosis: an update. *Hepatology* 2009; 49:2087.
8. Schrier, RW, Arroyo, V, Bernardi, M, et al. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. *Hepatology* 1988; 8:1151.
9. Gines, P, Fernandez-Esparrach, G, Arroyo, V, et al. Pathogenesis of ascites in cirrhosis. *Semin Liver Dis* 1997; 17:175.
10. Vorobioff, J, Bredfeldt, JE, Groszmann, RJ. Increased blood flow through the portal system in cirrhotic rats. *Gastroenterology* 1984; 87:1120.
11. Cardenas, A, Gines, P. Pathobiology, Evaluation, and Treatment. In: *Portal Hypertension*. Sanyal, AJ, Shah, VH (Eds), Humana Press 2005. p. 65.
12. Groszmann, RJ. Hyperdynamic circulation of liver disease 40 years later: Pathophysiology and clinical consequences. *Hepatology* 1994; 20:1359.
13. Maroto, A, Gines, P, Arroyo, V, et al. Brachial and femoral artery blood flow in cirrhosis: Relationship to kidney dysfunction. *Hepatology* 1993; 17:788.
14. Abelmann, WH. Hyperdynamic circulation in cirrhosis: A historical perspective. *Hepatology* 1994; 20:1356.
15. Kravetz, D, Ardenium, M, Bosch, J, et al. Hyperglucagonemia and hyperkinetic circulation after portocaval shunt in the rat. *Am J Physiol* 1987; 252:G257.

16. Guarner, F, Guarner, C, Prieto, et al. Increased synthesis of systemic prostacyclin in cirrhotic patients. *Gastroenterology* 1986; 90:687.
17. Guarner, C, Soriano, G, Such, J, et al. Systemic prostacyclin in cirrhotic patients. Relationship with portal hypertension and changes after intestinal decontamination. *Gastroenterology* 1992; 102:303.
18. Ros, J, Jimenez, W, Lamas, S, et al. Nitric oxide production in arterial vessels of cirrhotic rats. *Hepatology* 1995; 21:554.
19. Guarner, C, Soriano, G, Tomas, A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: Relationship to endotoxemia. *Hepatology* 1993; 18:1139.
20. Sieber, CC, Lopez-Talavera, JC, Groszmann, RJ. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. *Gastroenterology* 1993; 104:1750.
21. Wiest, R, Das, S, Cadelina, G, et al. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. *J Clin Invest* 1999; 104:1223.
22. Battista, S, Bar, F, Mengozzi, G, et al. Systemic and portal nitric oxide and endothelin-1 levels in cirrhotic patients. *J Hepatol* 1995; Suppl 1:73 (A).
23. Albillos, A, de la, Hera A, Gonzalez, M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. *Hepatology* 2003; 37:208.
24. Frances, R, Benlloch, S, Zapater, P, et al. A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. *Hepatology* 2004; 39:484.
25. Asbert, M, Gines, A, Gines, P, et al. Circulating levels of endothelin in cirrhosis. *Gastroenterology* 1993; 104:1485.
26. Wong, F, Massie, D, Hsu, P, Dudley F. Renal response to a saline load in well-compensated alcoholic cirrhosis. *Hepatology* 1994; 20:873.
27. Wensing, G, Lotterer, E, Link, I, et al. Urinary sodium balance in patients with cirrhosis: Relationship to quantitative parameters of liver function. *Hepatology* 1997; 26:1149.
28. Arroyo, V, Claria, J, Gaya, J, et al. Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. *Semin Liver Dis* 1994; 14:44.
29. Biggins SW, Rodriguez HJ, Bacchetti P, et al. Serum sodium predicts mortality in patients listed for liver transplantation. *Hepatology* 2005;41:32.
30. Sacerdoti, D, Bolognesi, M, Merkel, C, et al. Renal vasoconstriction in cirrhosis evaluated by duplex Doppler ultrasonography. *Hepatology* 1993; 17:219.

31. Guevara, M, Gines, P, Fernandez-Esparrach, G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. *Hepatology* 1998; 27:35.
32. Uriz, J, Gines, P, Cardenas, A, et al. Terlipressin plus albumin infusion: An effective and safe therapy of hepatorenal syndrome. *J Hepatol* 2000; 33:43.
33. Runyon, BA. Management of adult patients with ascites due to cirrhosis. *Hepatology* 1998; 27:264.
34. Runyon, BA. Care of patients with ascites. *N Engl J Med* 1994; 330:337.
35. Pockros, PJ, Esrason, KT, Nguyen, C, et al. Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. *Gastroenterology* 1992; 103:1302.
36. Caldwell, SH, Oelsner, DH, Iezzoni, JC, et al. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease. *Hepatology* 1999; 29:664.
37. Runyon, BA, Hoefs, JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. *Hepatology* 1988; 8:1104.
38. Cappell, MS, Shetty, V. A multicenter, case-controlled study of the clinical presentation and etiology of ascites and of the safety and efficacy of diagnostic abdominal paracentesis in HIV seropositive patients. *Am J Gastroenterol* 1994; 89:2172.
39. Cattau, E, Benjamin, SB, Knuff, TE, et al. The accuracy of the physical exam in the diagnosis of suspected ascites. *JAMA* 1982; 247:1164.
40. Inadomi, J, Cello, JP, Koch, J. Ultrasonographic determination of ascitic fluid. *Hepatology* 1996; 24:549.
41. Moore, KP, Wong, F, Gines, P, et al. The management of ascites in cirrhosis: report in the consensus conference of the International Ascites Club. *Hepatology* 2003; 38:258.
42. Hui, JY, Woo, PC, Kan, PS, Tang, AP. A woman with ascites and abdominal masses. *Lancet* 2000; 355:546.
43. Sakai, H, Sheer, TA, Mendler, MH, Runyon, BA. Choosing the location for non-image guided abdominal paracentesis. *Liver Int* 2005; 25:984.
44. Such, J, Runyon, BA. Spontaneous bacterial peritonitis. *Clin Infect Dis* 1998; 27:669.
45. Runyon, BA, Montano, AA, Akriviadis, EA, et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. *Ann Intern Med* 1992; 117:215.
46. Runyon, BA, Antillon, MR, Akriviadis, EA, McHutchison, JG. Bedside inoculation of blood culture bottles with ascitic fluid is superior to delayed inoculation in the detection of spontaneous bacterial peritonitis. *J Clin Microbiol* 1990; 28:2811.

47. Runyon, BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. *Gastroenterology* 1986; 91:1343.
48. al Karawi, MA, Mohamed, AE, Yasawy, MI, et al. Protean manifestation of gastrointestinal tuberculosis: Report on 130 patients. *J Clin Gastroenterol* 1995; 20:225.
49. Hillebrand, DJ, Runyon, BA, Yasmineh, WG, Rynders, GP. Ascitic fluid adenosine deaminase insensitivity in detecting tuberculosis peritonitis in the United States. *Hepatology* 1996; 24:1408.
50. Cardenas A, Arroyo V. Management of ascites and hydrothorax. *Best Pract. Res. Clin. Gastroenterol.* 2007; 21: 55–75.
51. Leung W, Wong F. Medical management of ascites. *Expert Opin. Pharmacother.*2011; 12: 1269–83.
52. Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. *Hepatology*2009; 49: 2087–107.
53. Santos J, Planas R, Pardo A et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. *J. Hepatol.*2003; 39: 187–92.
54. Angeli P, Della Pria M, De Bei E et al. Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. *Hepatology*1994; 19: 72–9.
55. Bolondi L, Piscaglia A, Gatta A et al., DOC (Decrease Of Complications in cirrhosis) Study Group. Effect of potassium canrenoate, an anti-aldosterone agent, on incidence of ascites and variceal progression in cirrhosis. *Clin. Gastroenterol. Hepatol.*2006; 4: 1395–402.
56. Angeli P, Fasolato S, Mazza E et al. Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial. *Gut*2010; 59: 98–104.
57. Shear L, Ching S, Gabuzda GJ. Compartmentalization of ascites and edema in patients with hepatic cirrhosis. *N. Engl. J. Med.*1970; 282: 1391–6.
58. Pinto-Marques P, Vieira A. Urinary sodium/potassium ratio on random sample as a useful tool to assess diuretic-induced natriuresis on chronic liver disease-associated ascites. *Am. J. Gastroenterol.* 2007; 102: 212–13.
59. Wong F. Drug insight: the role of albumin in the management of chronic liver disease. *Nat. Clin. Pract. Gastroenterol. Hepatol.*2007; 4: 43–51.
60. Fernández J, Monteagudo J, Bargallo X et al. A Randomized unblinded pilot study comparing albumin versus hydroethyl starch in spontaneous bacterial peritonitis. *Hepatology*2005; 42: 627–34.

61. Gentilini P, Casini-Raggi V, Di Fiore G et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. *J. Hepatol.*1999; 30: 639–45.
62. Romanelli RG, La Villa G, Barletta G et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. *World J. Gastroenterol.*2006; 12: 1403–7.
63. Salerno F, Guevara M, Bernardi M et al. Refractory ascites, pathogenesis, definition, and therapy of a severe complication in cirrhotic patients. *Liver Int.*2010; 30: 937–47.
64. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. *J Hepatol* 2010;53:397-417.
65. Stiehm, AJ, Mendler, MH, Runyon, BA. Detection of diuretic-resistance or diuretic-sensitivity by the spot urine Na/K ratio in 729 specimens from cirrhosis with ascites: approximately 90% accuracy compared to 24-hr urine Na excretion. *Hepatology* 2002; 36:222A.
66. Pockros, PJ, Esrason, KT, Nguyen, C, et al. Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. *Gastroenterology* 1992; 103:1302.
67. Han, SH, Reynolds, TB, Fong, TL. Nephrogenic ascites: Analysis of 16 cases and review of the literature. *Medicine* 1998; 77:233.
68. Salo, J, Guevara, M, Fernandez-Esparrach, G, et al. Impairment of renal function during moderate physical exercise in cirrhotic patients with ascites: Relationship with the activity of neurohumoral systems. *Hepatology* 1997; 25:1338.
69. Gines, P, Quintero, E, Arroyo, V, et al. Compensated cirrhosis: Natural history and prognostic factors. *Hepatology* 1987; 7:122.
70. D'Amico, G, Morabito, A, Pagliaro, L, et al. Survival and prognostic indicators in compensated and decompensated cirrhosis. *Dig Dis Sci* 1986; 31:468.
71. Bories, P, Garcia-Compean, D, Michel, H, et al. The treatment of refractory ascites by the LeVeen shunt: A multi-center controlled trial (57 patients). *J Hepatol* 1986; 3:212.
72. Arroyo, V, Bosch, J, Gaya, J, et al. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. *Ann Intern Med* 1981; 94:198.
73. Kalambokis, GN, Tsianos, EV. Vasoconstrictor therapy for patients with cirrhosis with ascites but without hepatorenal syndrome. *Hepatology* 2008; 48:686.
74. Gines, P, Tito, L, Arroyo, V, et al. Randomized study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. *Gastroenterology* 1988; 94:1493.
75. Kravetz, D, Romero, G, Argonz, J, et al. Total volume paracentesis decreases variceal pressure, size, and variceal wall tension in cirrhotic patients. *Hepatology* 1997; 25:59.

76. Duggal, P, Farah, KF, Anghel, G, et al. Safety of paracentesis in inpatients. *Clin Nephrol* 2006; 66:171.
77. Runyon, BA, Antillon, MR, Montano, AA. Effect of diuresis versus therapeutic paracentesis on ascitic fluid opsonic activity and serum complement. *Gastroenterology* 1989; 97:158.
78. Luca, A, Feu, F, Garcia-Pagan, JC, et al. Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites. *Hepatology* 1994; 20:30.
79. Evans, LT, Kim, WR, Poterucha, JJ, Kamath, PS. Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. *Hepatology* 2003; 37:897.
80. Runyon, BA. Patient selection is important in studying the impact of large-volume paracentesis on intravascular volume. *Am J Gastroenterol* 1997; 92:371.
81. Luca, A, Garcia-Pagan, JC, Bosch, J, et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. *Hepatology* 1995; 22:753.
82. Singh, V, Dheerendra, PC, Singh, B, et al. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. *Am J Gastroenterol* 2008; 103:1399.
83. Somberg, KA, Lake, JR, Tomlanovich, SJ, et al. Transjugular intrahepatic portosystemic shunts for refractory ascites: Assessment of clinical and hormonal response and renal function. *Hepatology* 1995; 21:709.
84. Lebrec, D, Giuily, N, Hadengue, A, et al. Transjugular intrahepatic portosystemic shunts: Comparison with paracentesis in patients with cirrhosis and refractory ascites: A randomized trial. French Group of Clinicians and a Group of Biologists. *J Hepatol* 1996; 25:135.
85. Saab, S, Nieto, JM, Ly, D, Runyon, BA. TIPS versus paracentesis for cirrhotic patients with refractory ascites. *Cochrane Database Syst Rev* 2004; :CD004889.
86. D'Amico, G, Luca, A, Morabito, A, et al. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. *Gastroenterology* 2005; 129:1282.
87. Salerno, F, Camma, C, Enea, M, et al. Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites: A Meta-analysis of Individual Patient Data. *Gastroenterology* 2007; 133:825.
88. Kamath, PS, Wiesner, RH, Malinchoc, M, et al. A model to predict survival in patients with end-stage liver disease. *Hepatology* 2001; 33:464.
89. Rossle, M, Ochs, A, Gulberg, V, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. *N Engl J Med* 2000; 342:1701.

90. Gines, P, Uriz, J, Calahorra, B, Garcia-Tsao, G. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. *Gastroenterology* 2002; 123:1839.
91. Sanyal, AJ, Genning, C, Reddy, KR, et al. The North American Study for the Treatment of Refractory Ascites. *Gastroenterology* 2003; 124:634.
92. Salerno, F, Merli, M, Riggio, O, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. *Hepatology* 2004; 40:629.
93. Martinet, JP, Fenyves, D, Legault, L, et al. Treatment of refractory ascites using transjugular intrahepatic portosystemic shunt (TIPS): A caution. *Dig Dis Sci* 1997; 42:161.
94. Bureau, C, Garcia-Pagan, JC, Otal, P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. *Gastroenterology* 2004; 126:469.
95. Boyer TD, Haskal ZJ. American Association for the Study of Liver Diseases Practice Guidelines: the role of transjugular intrahepatic portosystemic shunt creation in the management of portal hypertension. *J Vasc Interv Radiol* 2005; 16:615.
96. Gines, P, Arroyo, V, Vargas, V, et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. *N Engl J Med* 1991; 325:829.
97. Runyon, BA. Ascites and spontaneous bacterial peritonitis. In: Sleisenger and Fordtran's *Gastrointestinal and Liver Disease. Pathophysiology/Diagnosis/Management*, 7th ed, Feldman, M, Friedman, LS, Sleisenger, MH (Eds). WB Saunders, Philadelphia 2002. p.1517.
98. Rosemurgy, AS, Goode, SE, Zwiebel, BR, et al. A prospective trial of transjugular intrahepatic portosystemic stent shunts versus small-diameter prosthetic H-graft portacaval shunts in the treatment of bleeding varices. *Ann Surg* 1996; 224:378.
99. Chang, CY, Singal, AK, Ganeshan, SV, et al. Use of splenic artery embolization to relieve tense ascites following liver transplantation in a patient with paroxysmal nocturnal hemoglobinuria. *Liver Transpl* 2007; 13:1532.
100. Licata, G, Tuttolomondo, A, Licata, A, et al. Clinical Trial: High-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites. *Aliment Pharmacol Ther* 2009; 30:227.
101. Fernandez J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. *Gastroenterology* 2007;133:818-24.
102. Fernandez J, Navasa M, Gomez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. *Hepatology* 2002;35:140-8.

103. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. *J Hepatol* 2000;32:142-53.
104. Chu CM, Chang KY, Liaw YF. Prevalence and prognostic significance of bacterascites in cirrhosis with ascites. *Dig Dis Sci* 1995;40:561-5.
105. Terg R, Levi D, Lopez P, et al. Analysis of clinical course and prognosis of culture-positive spontaneous bacterial peritonitis and neutrocytic ascites. Evidence of the same disease. *Dig Dis Sci* 1992;37:1499-504.
106. Arvaniti V, D'Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. *Gastroenterology* 2010;139:1246-56, 1256.e1-5.
107. Appenrodt B, Grunhage F, Gentemann MG, et al. Nucleotidebinding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. *Hepatology* 2010;51:1327-33.
108. Wiest R. Role of bacterial infections for hepatorenal syndrome. In: Gerbes A, ed. *Frontiers in Gastrointestinal Research. Ascites, Hyponatremia and hepatorenal syndrome*. Basel, Switzerland: Krager, 2010.
109. Guarner C, Gonzalez-Navajas JM, Sanchez E, et al. The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation. *Hepatology* 2006;44:633-9.
110. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. *Hepatology* 2005;41:422-33.
111. Yan AW, Fouts DE, Brandl J, et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. *Hepatology* 2011;53:96-105.
112. Bauer TM, Steinbruckner B, Brinkmann FE, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. *Am J Gastroenterol* 2001;96:2962.
113. Ramachandran A, Prabhu R, Thomas S, et al. Intestinal mucosal alterations in experimental cirrhosis in the rat: role of oxygen free radicals. *Hepatology* 2002;35:622-9.
114. Dunn DL, Barke RA, Ahrenholz DH, et al. The adjuvant effect of peritoneal fluid in experimental peritonitis. Mechanism and clinical implications. *Ann Surg* 1984;199:37-43.
115. Gabele E, Muhlbauer M, Paulo H, et al. Analysis of monocyte chemotactic protein-1 gene polymorphism in patients with spontaneous bacterial peritonitis. *World J Gastroenterol* 2009;15:5558-62.
116. Joyce LD, Hau T, Hoffman R, et al. Evaluation of the mechanism of zymosan-induced resistance to experimental peritonitis. *Surgery* 1978;83:717-25.

117. Such J, Guarner C, Enriquez J, et al. Low C3 in cirrhotic ascites predisposes to spontaneous bacterial peritonitis. *J Hepatol* 1988;6:80-4.
118. Novella M, Sola R, Soriano G, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. *Hepatology* 1997;25:532-6.
119. Wiest R, Leidl F, Kopp A, et al. Peritoneal fluid adipokines: ready for prime time? *Eur J Clin Invest* 2009;39:219-29.
120. Altman C, Grange JD, Amiot X, et al. Survival after a first episode of spontaneous bacterial peritonitis. Prognosis of potential candidates for orthotopic liver transplantation. *J Gastroenterol Hepatol* 1995;10:47-50.
121. Berres ML, Schnyder B, Yagmur E, et al. Longitudinal monocyte human leukocyte antigen-DR expression is a prognostic marker in critically ill patients with decompensated liver cirrhosis. *Liver Int* 2009;29:536-43.
122. Nischalke HD, Berger C, Aldenhoff K, et al. Toll-like receptor (TLR) 2 promotor and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. *J Hepatol* 2011;55:1010-16.
123. Trikudanathan G, Israel J, Cappa J, et al. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis. *Int J Clin Pract* 2011;65:674-8.
124. Worlicek M, Knebel K, Linde HJ, et al. Splanchnic sympathectomy prevents translocation and spreading of *E coli* but not *S aureus* in liver cirrhosis. *Gut* 2010;59:1127-34.
125. Chinnock B, Afarian H, Minnigan H, et al. Physician clinical impression does not rule out spontaneous bacterial peritonitis in patients undergoing emergency department paracentesis. *Ann Emerg Med* 2008;52:268-73.
126. Albillos A, Cuervas-Mons V, Millan I, et al. Ascitic fluid polymorphonuclear cell count and serum to ascites albumin gradient in the diagnosis of bacterial peritonitis. *Gastroenterology* 1990;98:134-40.
127. Stassen WN, McCullough AJ, Bacon BR, et al. Immediate diagnostic criteria for bacterial infection of ascitic fluid. Evaluation of ascitic fluid polymorphonuclear leukocyte count, pH, and lactate concentration, alone and in combination. *Gastroenterology* 1986;90:1247-54.
128. Gonzalez-Navajas JM, Bellot P, Frances R, et al. Presence of bacterial-DNA in cirrhosis identifies a subgroup of patients with marked inflammatory response not related to endotoxin. *J Hepatol* 2008;48:61-7.
129. Zapater P, Frances R, Gonzalez-Navajas JM, et al. Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis. *Hepatology* 2008;48:1924-31.

130. Siersema PD, de Marie S, van Zeijl JH, et al. Blood culture bottles are superior to lysis-centrifugation tubes for bacteriological diagnosis of spontaneous bacterial peritonitis. *J Clin Microbiol* 1992;30:667-9.
131. Parsi MA, Saadeh SN, Zein NN, et al. Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis. *Gastroenterology* 2008;135:803-7.
132. Runyon BA, Hoefs JC. Ascitic fluid analysis in the differentiation of spontaneous bacterial peritonitis from gastrointestinal tract perforation into ascitic fluid. *Hepatology* 1984;4:447-50.
133. Wu SS, Lin OS, Chen YY, et al. Ascitic fluid carcinoembryonic antigen and alkaline phosphatase levels for the differentiation of primary from secondary bacterial peritonitis with intestinal perforation. *J Hepatol* 2001;34:215-21.
134. Song KH, Jeon JH, Park WB, et al. Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase- producing *Escherichia coli* and *Klebsiella* species: a retrospective matched case-control study. *BMC Infect Dis* 2009;9:41.
135. Merli M, Lucidi C, Giannelli V, et al. Cirrhotic patients are at risk for health care-associated bacterial infections. *Clin GastroenterolHepatol* 2010;8:979-85.
136. Navasa M, Follo A, Llovet JM, et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis . *Gastroenterology* 1996;111:1011-17.
137. Angeloni S, Leboffe C, Parente A, et al. Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice. *World J Gastroenterol* 2008;14:2757-62.
138. Piroth L, Pechinot A, Minello A, et al. Bacterial epidemiology and antimicrobial resistance in ascitic fluid: a 2-year retrospective study. *Scand J Infect Dis* 2009;41:847-51.
139. Kock R, Becker K, Cookson B, et al. Methicillin-resistant *Staphylococcus aureus* (MRSA): burden of disease and control challenges in Europe. *Euro Surveill* 2010;15:19688.
140. Park YH, Lee HC, Song HG, et al. Recent increase in antibiotic-resistant microorganisms in patients with spontaneous bacterial peritonitis adversely affects the clinical outcome in Korea. *J Gastroenterol Hepatol* 2003;18:927-33.
141. Rodriguez-Bano J, Picon E, Gijon P, et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing *Escherichia coli*: risk factors and prognosis. *Clin Infect Dis* 2010;50:40-8.
142. Runyon BA. Monomicrobial nonneutrocytic bacterascites: a variant of spontaneous bacterial peritonitis. *Hepatology* 1990;12:710-15.

143. Heo J, Seo YS, Yim HJ, et al. Clinical features and prognosis of spontaneous bacterial peritonitis in Korean patients with liver cirrhosis: a multicenter retrospective study. *Gut Liver* 2009;3:197-204.
144. Fong TL, Akriviadis EA, Runyon BA, et al. Polymorphonuclear cell count response and duration of antibiotic therapy in spontaneous bacterial peritonitis. *Hepatology* 1989;9:423-6.
145. Ginès P, Schrier RW. Renal failure in cirrhosis. *New Engl J Med*. 2009;361:1279–1290
146. Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome. *J Hepatol*. 2008;48:S93–S103.
147. Thabut D, Massard J, Gangloff A, et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. *Hepatology*. 2007;46:1872-1882.
148. Oliver JA, Verna EC. Afferent mechanisms of sodium retention in cirrhosis and hepatorenal syndrome. *Kidney Int*. 2010;77:669-680.
149. Fernandez-Seara J, Prieto J, Quiroga J, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. *Gastroenterology*. 1989;97:1304-1312.
150. Moreau R, Lebrec D. Endogenous factors involved in the control of arterial tone in cirrhosis. *J Hepatol*. 1995;22:370-376.
151. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. *Hepatology*. 1996;23:164-176.
152. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. *Gut*. 2007;56:1310-1318.
153. Arroyo V, Fernandez J, Gines P. Pathogenesis and treatment of hepatorenal syndrome. *Semin Liver Dis*. 2008;28:81-95.
154. Boyer T, Sanyal AJ, Garcia-Tsao G, et al. Terlipressin Study Group: predictors of response to terlipressin plus albumin and hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. *J Hepatol*. 2011;55:315-321.
155. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. *J Hepatol*. 2010;53:397-417.
156. Fernandez J, Escorsell A, Zabalza M, et al. Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hydrocortisone on survival. *Hepatology*. 2006;44:1288-1295.
157. Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. *Gastroenterology*. 2001;120:726-748.

158. Boyer T, Sanyal AJ, Garcia-Tsao G, et al. Terlipressin Study Group: predictors of response to terlipressin plus albumin and hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. *J Hepatol*. 2011;55:315-321.
159. Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 a hepatorenal syndrome: a meta-analysis of randomized controlled trials. *J Gastroenterol Hepatol*. 2010;25:880-885.
160. Nazar A, Pereira GH, Guevara M, et al. Predictors of response to therapy with Terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. *Hepatology*. 2010;51:219-226.
161. Gluud LI, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. *Hepatology*. 2010;51:576-584.
162. Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for hepatorenal syndrome. *Aliment Pharmacol Ther*. 2006;24:935-944.
163. Esralian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/midodrine therapy significantly improves renal function and 30 day survival in patients with type 1 hepatorenal syndrome. *Dig Dis Sci*. 2007;52:742-748.
164. Gines P, Schrier RW. Renal failure in cirrhosis. *N Engl J Med*. 2009;361:1279-1290.
165. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. *Hepatology*. 2004;40:55-64.
166. Cardenas A. Hepatorenal syndrome: a dreaded complication of end-stage liver disease. *Am J Gastroenterol*. 2005;100:460-467.
167. Arroyo V, Gines P, Gerbes AL, Dudley FJ, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. *Hepatology*. 1996;23:164-176.
168. Exner M, Schwarzwinger I. Targeting the dust. *Br J Haematol* 2001; 114:739.
169. Smith GL, Shlipak MG, Havranek EP, Foody JM, Masoudi FA, Rathore SS, et al. Serum Urea Nitrogen, Creatinine and Estimators of Renal Function. *Arch Intern Med* 2006; 166(10):1134-42.
170. Spahr L, Jean-Pierre V, Tran HK, Pomier-Layrargues G. Furosemide-Induced natriuresis as a test to identify cirrhotic patients with refractory ascites. *Hepatol* 2001; 33(1):29.
171. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. *N Engl J Med* 2000; 342:1266.
172. Balistren DF, Rej R. Liver functions. In: *Fundamentals of clinical chemistry*. Burtis AC, Ashwood ER, editors. 4th ed. Philadelphia: WB Saunders Company 1996; 539-68.

173. Silvermen LM, Chrsterson RH. Aminoacid and proteins. In: Fundamentals of clinical chemistry. Burtis AC, Ashwood ER, editors. 4th ed. Philadelphia: WB Saunders Company 1996; 240-82.
174. Dacie JV, Lewis SM. Investigations of bleeding tendency. In: Practical hematology. 8th ed. Edinburgh, London: Churchill Livingstone 1994; 5:317-50.
175. Pawlotsky JM. Use and interpretation of virology tests for hepatitis C. *Hepatology* 2002; 36:65-73.
176. Nevens F, Goubau P, Eyken P. Hepatitis B virus sero-diagnosis. *Liver* 1999; 13(1):15-9.
177. Stothard JR, Kabatereine NB, Tukahebwa EM, Kazbw F, Mathieson W, Webster JP, et al. Field evaluation of the Meade Readiview handheld microscope for diagnosis of intestinal schistosomiasis in Ugandan school children. *Am J Trop Med Hyg* 2005; 73(5):949-55.
178. Trevisani F, Mazzella G, Caraceni P. Serum alpha- fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: Influence of HBsAg and anti-HCV status. *J Hepatol* 2001; 34:603-5.
179. Jean-Paul C, Thierry T, Delphine W, Emilie M, Olivier B, Frances S, et al. C-Reactive protein predicts short-term mortality in patients with cirrhosis. *Journal of Hepatology* 2012; 56(6):1299-304.
180. Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. *Hepatology* 1988; 8(5):1104-9.
181. Somberg KA, Lake JR, Tomlanovich SJ, Laberge JM, Feldstein V, Bass Nathan M. Transjugular intrahepatic portosystemic shunts for refractory ascites: Assessment of clinical and hormonal response and renal function. *Hepatology* 1995; 21(3):709-16.
182. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. *Br J Surg* 1973; 60(8):646-9.
183. Child CG, Turcotte JG. Surgery and portal hypertension. In: The liver and portal hypertension. Child CG, editors. Philadelphia: Saunders 1964; 50-64.
184. Biller DS, Kantrowitz B, Miyabayashi T. Ultrasonography of Diffuse Liver Disease: A Review. *Journal of Veterinary Internal Medicine* 1992; 6(2):71-6.
185. Foroutani A, Garland AM, Berber E, String A, Engle K, Ryan TL, et al. Laparoscopic Ultrasound vs Triphasic Computed Tomography for Detecting Liver Tumors. *Arch Surg* 2000; 135(8):933-8.
186. Kim SU, Han KH, Nam CM, Park JY, Kim do Y, Chon CY, et al. Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. *J Gastroenterol Hepatol* 2008;23:1722-7.

187. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. *Hepatology* 1996;23:164-76.
188. Forns X, Ginès A, Ginès P, Arroyo V. Management of ascites and renal failure in cirrhosis. *Semin Liver Dis* 1994;14:82-96.
189. Seo JH, Kim SU, Park JY, et al. Predictors of refractory ascites development in patients with hepatitis B-related cirrhosis hospitalized to control ascites decomposition. *Yonsei Med J* 2013; 54: 145-53.
190. Ennaifer R, Elleuch N, Romdhane H, et al. Refractory ascites in cirrhosis : Prevalence and predictive factors. *J Liver* 2014 : 3 : 3-4.
191. Rossle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax : a critical update. *Gut* 2010 ; 59 : 988-1000.
192. Runyon BA. Management of adult patients with ascites due to cirrhosis. *Hepatology* 2009 ; 49 : 2087-2107.
193. Moreau R, Deleuge P, Durand F, et al. Clinical characteristics and outcome of patients with cirrhosis and refractory ascites. *Liver Int* 2004 ; 24 : 457-64.
194. Planas R, Montoliu S, Balleste B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. *Clin Gastroenterol Hepatol* 2006 ; 4 : 1385-94.
195. Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. *Hepatology* 2003; 38: 258-66.
196. Moini M, Hoseini MK, Taghavi SA, et al. Hyponatremia a valuable predictor of early mortality in patients with cirrhosis listed for liver transplantation. *Clin Transplant* 2011; 25 : 638-45.
197. Bernardi M, Laffi G, Salvagini M, et al. Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content. *Liver* 1993; 13 : 156-62.
198. Angeli P, Wong F, Watson H, et al. Hyponatremia in cirrhosis : result of a patient population survey. *Hepatology* 2006 : 44 : 1535-42.
199. Biggins SW, Kim WR, Saab S, et al. Evidence-based incorporation of serum sodium concentration into MELLD. *Gastroenterology* 2006 ; 130 : 1652-60.
200. Heuman DM, Abou-Assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. *Hepatology* 2004 ; 40 : 802-10.
201. Bajaj JS, Wong F, et al. Bacterial infection in end-stage liver disease : current challenges and future directions. *Gut* 2012; 61 : 1219-25.

202. Arvaniti V, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. *Gastroenterology* 2010; 139 : 1246-56.
203. Perdimo CG, Alves A. Renal impairment after spontaneous bacterial peritonitis : incidence and prognosis. *Canadian Journal of Gastroenterology*. 2003; 17: 187-90.
204. Fasolato S, Angelio P, et al. Renal failure and bacterial infections in patients with cirrhosis : epidemiology and clinical features. *Hepatology* 2007; 45 : 223-29.
205. Papp M, Vitalis Z, et al. Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections. *Liver International* 2012 ; 32 : 603-11.
206. Tandon P, Tsao G, et al. Bacterial infection, sepsis, and multiorgan failure in cirrhosis. *Semin Liver Dis* 2008; 28 : 26-41.
207. Terra C, Guevara M, Torre A. Renal function in patients with cirrhosis and sepsis. *Gastroenterology* 2005 ; 129: 1944-53.
208. Shorman DS, Fish DN. Assessing renal function in cirrhotic patients. *Am J Kidney Dis* 2003;41:269-78.
209. Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. *Gut* 2005;54:691-697.
210. Rossi S, Rosa L, Ravetta V, et al. Contrast-enhanced versus conventional and color Doppler sonography for the detection of thrombosis of the portal and hepatic venous systems. *AJR Am J Roentgenol* 2006; 186: 763–73.
211. Amitrano L, Guardascione MA, Brancaccio V, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. *J Hepatol* 2004; 40: 736–41.
212. Bruix J, Sherman M. AASLD practice guideline: management of hepatocellular carcinoma. *Hepatology* 2005;42:1208-1236.
213. Sugano, S, Miyoshi, K, Suzuki, T, et al. Intrahepatic arteriovenous shunting due to hepatocellular carcinoma and cirrhosis, and its change by transcatheter arterial embolization. *Am J Gastroenterol* 1994; 89:184.
214. Bruix, J, Sherman, M. Management of hepatocellular carcinoma. *Hepatology* 2005; 42:1208.

## المخلص العربي

تليف الكبد أو تشمع الكبد، هو مصطلح للتعبير عن الكبد الذي استبدال نسيجه السليم بنسيج ليفي أو ندبات ويؤدي هذا الأمر الى فقدان الكبد لوظائفه وفشل الكبد. يحدث تشمع الكبد إثر الإصابة بداء كبدى مزمن، يلحق الضرر المستمر بالكبد ويسبب فشله في نهاية الأمر. وأكثر الأسباب شيوعاً للإصابة بتليف الكبد هي التهاب الكبد الوبائي من نوع (سي) خصوصاً في مصر، والتي لديها أعلى معدل انتشار في العالم، ويقدر معدل انتشار فيروس سي في عموم السكان ما بين ١٠% - ٢٢%.

حوالي ٤٠% من المرضى الذين يعانون من تليف الكبد بدون أعراض وربما يظلوا كذلك لفترات طويلة. وتليف الكبد أعراض تظهر في صورة فقدان الشهية وفقدان الوزن والإرهاق، من ناحية أخرى يمكن لتليف الكبد أن يؤدي الى مضاعفات مثل ارتفاع في نسبة الصفراء بالدم، استسقاء، التهاب الالتهاب البريتوني التلقائي الجرثومي، اعتلال الدماغ الكبدي، متلازمة الكبدية الكلوية، ونزف دوالي المريء من فرط ضغط الدم البابي. علاوة على ذلك المرضى الذين يعانون من تليف الكبد معرضون لخطر متزايد للإصابة بسرطان الكبد.

من خلال هذه الدراسة وجدنا أن حالات الاستسقاء المستعصي للعلاج تمثل ٥% - ١٠% من المرضى الذين يعانون من المرحلة المتأخرة من تليف الكبد مما يترتب عليه رفع نسبة حدوث الوفاة من ٢٠% - ٥٠% خلال عام.

الهدف من هذه الدراسة هو البحث عن الأسباب المؤدية الى عدم استجابة الاستسقاء الى العلاج الذي يتمثل في عقار مدرات البول.

تم تشخيص الحالات التي تعاني الاستسقاء المستعصي للعلاج تم عن طريق تناول التاريخ المرضي للحالات والكشف الإكلينيكي الكامل وفحص المرضى بالموجات الصوتية والتحليل الطبية، وفي بعض الحالات تم إجراء اشعة مقطعية على الكبد واشعة دوبلر على الوريد البابي.

ومن خلال هذه الدراسة التي أجريت على ٦٠ مريض يعانون من الاستسقاء المستعصي للعلاج تبين أن ١٣,٣% من المرضى يعانون من عدم الاستجابة لمدرات البول و ٨٦,٧% لا يتحملون الزيادة في جرعة مدرات البول بسبب الأعراض الجانبية الناتجة عن مدرات البول التي تتمثل في انخفاض ضغط الدم في ٢٨ حالة (٤٦,٦%)، حدوث الغيبوبة الكبدية في ٢٠ حالة (٣٣,٣%)، تدهور وظائف الكلى في ٤ حالات (٦,٦%).

ومن خلال هذه الدراسة وجد أن ٥٢ مريض (٨٦,٧%) يعانون من ارتفاع في نسبة الصفراء في الدم نتيجة تدهور حالة الكبد، ٩ حالات (١٥%) تعاني من التهاب البريتوني التلقائي الجرثومي، انخفاض نسبة الصوديوم في الدم في ١٦ حالة (٢٦,٦%) وارتفاع نبة البوتاسيوم بالدم في ١٢ حالة (٢٠%) بسبب استخدام عقار الداكتون.

أيضاً وجد من خلال هذه الدراسة أن ١٨ مريض (٣٠%) يعانون من سرطان الكبد و ١٢ مريض (٢٠%) يعانون من جلطة في الوريد البابي.

ومن خلال دراسة هذه النتائج تبين أن العوامل المؤدية الى الاستسقاء المستعصي في مرض تشمع الكبد هي فشل في وظائف الكبد أو التدهور في حالة التليف، التهاب البريتوني التلقائي الجرثومي، تدهور وظائف الكلى، جلطات الوريد البابي و سرطان الكبد.